The Role of Chemotherapy in the Management of Sinonasal and Ventral Skull Base Malignancies.
In most cases of advanced sinonasal and ventral skull base cancer, a multimodal treatment approach provides the best chance for improved outcomes. Depending on the tumor type and extent of disease, systemic chemotherapy has been shown to play an important role in neoadjuvant, concomitant, and adjuvant settings. The lack of randomized trials continues to limit its indications. Further high-quality studies are needed to understand ideal chemotherapeutic regimens and their role and sequential timing in sinonasal and ventral skull base cancer.
Department of Otolaryngology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, 243 Charles Street, Boston, MA 02114, USA. Electronic address: George_Scangas@meei.harvard.edu.
George A
GA
Scangas
Endoscopic Skull Base Surgery Program, Department of Otolaryngology - Head and Neck Surgery, Rhinology and Sinus Surgery, Otolaryngology Research, Neurological Institute of New Jersey, Rutgers New Jersey Medical School, 185 South Orange Avenue, Newark, NJ 07103, USA.
Jean Anderson
JA
Eloy
Division of Head and Neck Oncology, Massachusetts Eye and Ear Infirmary, Massachusetts General Hospital, Harvard Medical School, 243 Charles Street, Boston, MA 02114, USA.
Derrick T
DT
Lin
D017024:Chemotherapy, Adjuvant / Q000379:methods*; D006801:Humans; D010255:Paranasal Sinus Neoplasms / Q000473:pathology / Q000628:therapy*; D019291:Skull Base / Q000473:pathology*; D019292:Skull Base Neoplasms / Q000473:pathology / Q000628:therapy*
Chemotherapy; Multimodality therapy; Neoadjuvant chemotherapy; Sinonasal cancer; Sinonasal tumor; Systemic treatment